One cannabinoid we're especially excited about is CBGV (Cannabigerovarin)
In September 2025, an investigation published by the BMJ revealed that patients were being pushed towards the black market to purchase weight-loss drugs, which it suggested may be because of poor access to drugs on the NHS and the Mounjaro price hike
Conversely, incretin mimetics have a very low intrinsic hypoglycaemia risk when used alone, as their glucose-lowering effect is glucose-dependentinsulin secretion ceases when glucose normalises
This is generally related to the caloric deficit rather than the medication itself, and it typically resolves as caloric intake stabilizes
However, if infections persist despite adequate treatment and good glycaemic control, further investigation for azole-resistant Candida or non-albicans Candida species may be warranted
A few peptides are in early-stage clinical testing, and wider usage may be years away